Sign up to access all valuation multiples
Healius is Australia’s second-largest pathology provider and third-largest diagnostic imaging provider, though the latter business is set to be sold in early 2025. Pathology and imaging revenue is almost entirely earned via the public health Medicare system. Healius typically earns approximately 75% of revenue from pathology and 25% from diagnostic imaging.
1994
10.6K+
LTM Revenue $870M
LTM EBITDA $158M
$950M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Healius has a last 12-month revenue (LTM) of $870M and a last 12-month EBITDA of $158M.
In the most recent fiscal year, Healius achieved revenue of $1.1B and an EBITDA of -$218M.
Healius expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Healius valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $870M | XXX | $1.1B | XXX | XXX | XXX |
| Gross Profit | $732M | XXX | $978M | XXX | XXX | XXX |
| Gross Margin | 84% | XXX | 87% | XXX | XXX | XXX |
| EBITDA | $158M | XXX | -$218M | XXX | XXX | XXX |
| EBITDA Margin | 18% | XXX | -19% | XXX | XXX | XXX |
| EBIT | $13.9M | XXX | $42.1M | XXX | XXX | XXX |
| EBIT Margin | 2% | XXX | 4% | XXX | XXX | XXX |
| Net Profit | -$12.2M | XXX | -$415M | XXX | XXX | XXX |
| Net Margin | -1% | XXX | -37% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $232M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of August 29, 2025, Healius's stock price is AUD 1 (or $1).
Healius has current market cap of AUD 624M (or $401M), and EV of AUD 1.5B (or $950M).
See Healius trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $950M | $401M | XXX | XXX | XXX | XXX | $-0.02 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of August 29, 2025, Healius has market cap of $401M and EV of $950M.
Healius's trades at 0.9x EV/Revenue multiple, and -6.9x EV/EBITDA.
Equity research analysts estimate Healius's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Healius has a P/E ratio of -32.8x.
See valuation multiples for Healius and 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $401M | XXX | $401M | XXX | XXX | XXX |
| EV (current) | $950M | XXX | $950M | XXX | XXX | XXX |
| EV/Revenue | 1.1x | XXX | 0.9x | XXX | XXX | XXX |
| EV/EBITDA | 6.0x | XXX | -6.9x | XXX | XXX | XXX |
| EV/EBIT | 68.6x | XXX | 18.1x | XXX | XXX | XXX |
| EV/Gross Profit | 1.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | -32.8x | XXX | -1.2x | XXX | XXX | XXX |
| EV/FCF | 4.8x | XXX | 6.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialHealius's last 12 month revenue growth is 4%
Healius's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.
Healius's rule of 40 is -8% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Healius's rule of X is 29% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Healius and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 4% | XXX | -9% | XXX | XXX | XXX |
| EBITDA Margin | 18% | XXX | -12% | XXX | XXX | XXX |
| EBITDA Growth | 14% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -8% | XXX | -8% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 29% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 83% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Australian Clinical Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Integral Diagnostics | XXX | XXX | XXX | XXX | XXX | XXX |
| Sonic Healthcare | XXX | XXX | XXX | XXX | XXX | XXX |
| Bangkok Dusit Medical Services | XXX | XXX | XXX | XXX | XXX | XXX |
| Syngene International | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Healius acquired XXX companies to date.
Last acquisition by Healius was XXXXXXXX, XXXXX XXXXX XXXXXX . Healius acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was Healius founded? | Healius was founded in 1994. |
| Where is Healius headquartered? | Healius is headquartered in Australia. |
| How many employees does Healius have? | As of today, Healius has 10.6K+ employees. |
| Who is the CEO of Healius? | Healius's CEO is Mr. Paul R. Anderson. |
| Is Healius publicy listed? | Yes, Healius is a public company listed on ASX. |
| What is the stock symbol of Healius? | Healius trades under HLS ticker. |
| When did Healius go public? | Healius went public in 1998. |
| Who are competitors of Healius? | Similar companies to Healius include e.g. Australian Clinical Labs, Integral Diagnostics, Sonic Healthcare, Bangkok Dusit Medical Services. |
| What is the current market cap of Healius? | Healius's current market cap is $401M |
| What is the current revenue of Healius? | Healius's last 12 months revenue is $870M. |
| What is the current revenue growth of Healius? | Healius revenue growth (NTM/LTM) is 4%. |
| What is the current EV/Revenue multiple of Healius? | Current revenue multiple of Healius is 1.1x. |
| Is Healius profitable? | Yes, Healius is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Healius? | Healius's last 12 months EBITDA is $158M. |
| What is Healius's EBITDA margin? | Healius's last 12 months EBITDA margin is 18%. |
| What is the current EV/EBITDA multiple of Healius? | Current EBITDA multiple of Healius is 6.0x. |
| What is the current FCF of Healius? | Healius's last 12 months FCF is $198M. |
| What is Healius's FCF margin? | Healius's last 12 months FCF margin is 23%. |
| What is the current EV/FCF multiple of Healius? | Current FCF multiple of Healius is 4.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
